|
Showing 1 - 3 of
3 matches in All Departments
Antiplatelet therapy is the cornerstone of treatment of ischemic
cardiovascular disease and over the last few years spectacular
advancements in this field have been recorded. This is the first
comprehensive handbook entirely dedicated to all the aspects of
antiplatelet therapy. The book is divided into three main sections,
pathophysiology, pharmacology and therapy, for a total of 23
chapters. A large group of leading experts from different European
countries and from the USA, both from academia and industry, have
contributed to the book. Besides a detailed overview on the
pharmacology and clinical applications of all the currently used or
of the novel antiplatelet agents, innovative approaches (e.g.
intracellular signalling as an antiplatelet target, small RNAs as
platelet therapeutics, etc.) or unconventional aspects (e.g.
pharmacologic modulation of the inflammatory action of platelets
are also treated. The book is oriented to both basic investigators
and to clinicians involved with research on platelet inhibition or
with the clinical use of antiplatelet therapies.
Antiplatelet therapy is the cornerstone of treatment of ischemic
cardiovascular disease and over the last few years spectacular
advancements in this field have been recorded. This is the first
comprehensive handbook entirely dedicated to all the aspects of
antiplatelet therapy. The book is divided into three main sections,
pathophysiology, pharmacology and therapy, for a total of 23
chapters. A large group of leading experts from different European
countries and from the USA, both from academia and industry, have
contributed to the book. Besides a detailed overview on the
pharmacology and clinical applications of all the currently used or
of the novel antiplatelet agents, innovative approaches (e.g.
intracellular signalling as an antiplatelet target, small RNAs as
platelet therapeutics, etc.) or unconventional aspects (e.g.
pharmacologic modulation of the inflammatory action of platelets
are also treated. The book is oriented to both basic investigators
and to clinicians involved with research on platelet inhibition or
with the clinical use of antiplatelet therapies.
Thirty years have elapsed since the first description by S. A.
BERSON and R. S. Y ALOW of the basic principles of radioimmunoassay
(RIA). During this period of time, RIA methodology has been
instrumental to the growth of many areas of biomedical research,
including endocrinology, oncology, hematology, and pharmacology. It
has done so by providing a relatively simple universal tool
allowing, for the first time, the detection of endogenous mediators
that are present 12 10 in body fluids at concentrations as low as
10- _10- M. The fundamental nature of this discovery and the
wide-ranging fall-out of basic and clinical knowledge derived from
its application have been acknowledged by the many honors tributed
to its pioneers, including the Nobel Prize awarded to Dr. Y ALOW 10
years ago. Although several excellent books have been published
during the past decades covering various aspects of RIA
methodology, we felt the need, as pharmacologists, for a
comprehensive discussion of the methodological and conceptual
issues related to the main classes of mediators of drug action and
to drugs themselves. Thus, we gladly accepted the challenge
provided by the invitation to edit a volume of the Handbook of
Experimental Pharmacology on Radioimmunoassay in Basic and Clinical
Pharmacology. We tried to balance the emphasis placed on more
general aspects of the RIA methodology and that on specific
mediators.
|
|